Incanthera PLC Notice of Interim Results (6601H)
04 Décembre 2020 - 5:08PM
UK Regulatory
TIDMINC
RNS Number : 6601H
Incanthera PLC
04 December 2020
Incanthera plc
("Incanthera" or the "Company")
Notice of Interim Results
Investor Presentation
Incanthera plc (AQSE: INC) is pleased to announce that it will
report its interim results for the six months ended 30 September
2020, on Tuesday 8 December 2020.
The Company will provide a live presentation of its results via
the Investor Meet Company ("IMC") platform on Tuesday 8 December at
12.30 p.m.
The Company is committed to ensuring that there are appropriate
communication structures for all elements of its shareholder base
so that its strategy, business model and performance are clearly
understood.
-- Questions can be submitted pre-event via your IMC dashboard
or at any time during the live presentation via the "Ask a
Question" function. Although the Company may not be able to answer
every question it receives, it will address the most prominent
within the confines of information already in the public domain.
Responses to the Q&A from the live presentation will be
published at the earliest opportunity on the IMC platform. No
inside information will be given at the presentation.
-- Investor feedback can also be submitted directly to
management post-event (please see below for contact details).
Investors can sign up to Investor Meet Company for free and add
to meet Incanthera via:
https://www.investormeetcompany.com/incanthera-plc/register-investor
Investors who have already registered and added to meet the
Company will be automatically invited.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
The Directors of Incanthera accept responsibility for this
announcement.
For further information please contact:
Incanthera:
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney +44 (0) 20 3815 8880
- ends -
Notes to Editors
Incanthera is a specialist oncology company focused on
transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner within 12-18 months of listing.
The Company originated from the Institute of Cancer Therapeutics
(ICT) at the University of Bradford and, in addition to Sol, has
acquired and developed a portfolio of specific cancer-targeting
therapeutics through a Pipeline Agreement with the ICT and other
corporate acquisitions. Incanthera's strategy is to develop each
candidate in the portfolio from initial acquisition or discovery to
securing its future through commercially valuable partnerships at
the earliest opportunity in its development pathway.
The majority of conventional cancer treatments (other than
surgery) on the market are chemotherapy or radiotherapy based.
These are non-selective by nature and highly toxic to healthy
tissue as well as tumours. Accordingly, treatment can only be
delivered in carefully controlled doses over a limited period of
time. To address this problem directly, the Company has developed
sophisticated formulation and prodrug targeting technologies to
deliver treatment specifically to the tumour. Prodrugs are
chemically modified versions of pharmacologically active agents
which only become active when they reach a target, thus reducing
generalised toxicity in normal tissues, whilst enabling higher
doses to reach a target and therefore increase efficacy.
Incanthera's Board and management possess a broad range of
commercial, scientific and public company experience. In addition,
Incanthera benefits from a diverse, experienced team of advisers
who cover the necessary range of specialities required for all
aspects of the Company's business, and also has a number of
beneficial collaborative relationships with both clinicians and
clinical centres. In particular, the Pipeline Agreement with the
ICT, provides a strong working relationship with a world-recognised
oncology research institute and access to future pipeline
opportunities.
For more information on the Company please visit:
www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXEAKALEEKEFFA
(END) Dow Jones Newswires
December 04, 2020 11:08 ET (16:08 GMT)
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Incanthera (AQSE:INC)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024